成都先导(688222) - 2025 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2025 reached RMB 525.57 million, representing a year-on-year increase of 23.09%[2] - The net profit attributable to the parent company was RMB 114.02 million, showing a significant year-on-year growth of 122.01%[4] - The basic earnings per share increased to RMB 0.28, reflecting a growth of 115.38% compared to the previous year[3] - The total assets at the end of the reporting period amounted to RMB 1,955.93 million, up 11.35% year-on-year[4] - The company's operating profit was RMB 125.67 million, which is a 99.58% increase from the previous year[8] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 116.59 million, marking a 102.99% increase year-on-year[4] Business Segments - The core business segment, DEL, maintained steady growth and contributed to overall profit improvement[6] - The OBT segment showed significant revenue growth due to successful commercialization of small nucleic acid projects[6] Financial Stability - The company reported a decrease in fair value losses on financial liabilities, positively impacting overall financial performance[10] - There are no significant uncertainties affecting the accuracy of the performance report as of the announcement date[11]